Dasatinib
Src and Bcr/Abl inhibitor / Inhibits Src, Bcl/Abl and Lyn tyrosine kinases (IC50= 0.55, 3.0 and 8.5 nM respectively1,2. Suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells3.
Biochemicals & reagents
302962-49-8
BMS-354825
1) Lombardo et al. (2004), Discovery of N-2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a duel Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays; J. Med. Chem., 47 6658 2) Nam et al. (2005), Action of the Src family kinase inhibitor dasatinib (BMS-354825), on human prostate cancer cells; Cancer Res., 65 9185 3) Johnson et al. (2005), Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells; Clin. Cancer Res., 11 6924
-20°C
TARGET: Kinase -- PATHWAY: Cell cycle; Apoptosis inducer -- RESEARCH AREA: Cell death; Immunology -- DISEASE AREA: Cancer